Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines

Open Access
Publisher Website
Google Scholar
Abstract
Nine years ago, in his 1997 Morgan State College commencement address, President Bill Clinton announced a 10‐year goal for the development of an HIV/AIDS vaccine. A cornerstone of this plan was the establishment of a vaccine research center on the National Institutes of Health (NIH) campus in Bethesda, Maryland. We are now close to reaching 10 years and are unlikely to realize an effective HIV/AIDS vaccine by 2007. Nevertheless, the NIH Vaccine Research Center (VRC), which opened in 2001, has become a force in vaccine research and development and, in this issue of the Journal, publishes a pair of articles [1, 2] reporting the results of phase 1 human trials for its HIV/AIDS vaccines, which are now well into phase 2 studies. The vaccine strategy uses DNA to prime the immune response and a replication‐defective recombinant adenovirus serotype 5 (rAd5) vector to boost responses.

This publication has 0 references indexed in Scilit: